LENSAR (NASDAQ:LNSR) Releases Earnings Results, Beats Expectations By $1.38 EPS

LENSAR (NASDAQ:LNSR) released its quarterly earnings results on Friday. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $0.18 by $1.38, reports. The business had revenue of $13.43 million during the quarter, compared to analyst estimates of $13.40 million.

Here are the key takeaways from LENSAR’s conference call:

• LENSAR is independent again and rebuilding commercial momentum; management said distributor purchase orders were received post-quarter and international system shipments are expected this quarter, signaling early recovery of OUS placements.
• Recurring revenue strengthened — recurring revenue was $12.6 million, up 9% year-over-year and accounted for 94% of Q1 revenue, which management frames as a more durable business model.
• Headline net income was $36.3 million but was largely non-cash (warrant fair-value gain and a $10M acquisition deposit); adjusted EBITDA was negative $0.3M and cash on hand was $13.5M, highlighting limited near-term cash-generation and a reliance on operational recovery.
• Installed base and procedure trends show traction — 7 ALLY placements in Q1 (ALLY ~205 systems), total installed base ~440 (up 12% YoY), ~54,000 procedures in Q1, and U.S. market share of 23.4% with management expecting renewed share gains as placements resume.
• Product roadmap focused on expanding ALLY capabilities — management plans corneal applications, more robotic functions and automation of docking to extend technological leadership, but timing and commercial impact remain uncertain.

LENSAR Stock Performance

Shares of NASDAQ LNSR traded up $0.41 during trading hours on Friday, hitting $5.64. 153,766 shares of the stock were exchanged, compared to its average volume of 73,927. The company’s fifty day simple moving average is $7.39 and its two-hundred day simple moving average is $10.11. The company has a market cap of $68.24 million, a PE ratio of -1.94 and a beta of 0.84. LENSAR has a 1-year low of $5.06 and a 1-year high of $14.31.

Institutional Investors Weigh In On LENSAR

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNSR. Barclays PLC increased its stake in shares of LENSAR by 10.3% in the 4th quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after purchasing an additional 1,389 shares during the last quarter. LPL Financial LLC raised its stake in LENSAR by 11.3% during the fourth quarter. LPL Financial LLC now owns 17,922 shares of the company’s stock worth $208,000 after acquiring an additional 1,819 shares in the last quarter. Prelude Capital Management LLC acquired a new position in LENSAR during the third quarter worth about $145,000. One68 Global Capital LLC bought a new position in shares of LENSAR in the third quarter worth about $214,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of LENSAR in the 3rd quarter valued at approximately $125,000. 40.15% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LNSR. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENSAR in a research report on Tuesday, April 21st. BTIG Research upgraded LENSAR from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Tuesday, March 17th. Finally, Lake Street Capital raised LENSAR from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Wednesday, April 1st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.